Abbott (ABT) received FDA clearance and CE Mark for its Ultreon 3.0 Software. Ultreon 3.0 is an AI powered imaging platform that uses optical coherence tomography to give doctors real-time planning guidance while they perform minimally invasive procedures to open blocked heart arteries known as percutaneous coronary intervention.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/28/2026
- Abbott Expands Board and Enhances Equity Incentive Programs
- Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/27/2026
- Abbott announces new late-breaking data from four trials on PFA, CSP portfolios
- Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/24/2026